trial summary · NCT07741253
PRECISE-AFMR I: Transcatheter Mitral Valve Edge-to-Edge Repair for Atrial Functional Mitral Regurgitation in Patients at High Surgical Risk
PRECISE-AFMR I: A Prospective Randomized Controlled Trial of Transcatheter Mitral Valve Edge-to-Edge Repair in Patients With Atrial Functional Mitral Regurgitation at High Surgical Risk
Trial record from the TrialBase DB dataset, status RECRUITING, condition Atrial Functional, sponsored by China National Center for Cardiovascular Diseases. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
Atrial functional mitral regurgitation (AFMR) develops when enlargement and remodeling of the left atrium and mitral annulus prevent the mitral valve leaflets from closing completely, allowing blood to leak backward through the valve. For patients with significant AFMR who remain symptomatic despite medical treatment and are at high risk for surgery, it is uncertain whether adding transcatheter mitral valve edge-to-edge repair (TEER), a catheter-based procedure that brings the mitral valve leaflets together, provides better outcomes than medical treatment alone. PRECISE-AFMR I is a prospective, multicenter, randomized study that will enroll 182 adults with moderate-to-severe or severe AFMR, high or prohibitive surgical risk, and mitral valve anatomy suitable for TEER. Participants will be assigned in a 1:1 ratio to receive TEER plus optimized guideline-directed medical therapy (GDMT) or optimized GDMT alone. All participants will receive standardized medical care and will be followed for 12 months. The main effectiveness outcome is the occurrence of death from any cause or hospitalization for heart failure within 12 months. The main safety outcome is the occurrence of major device-related adverse events within 12 months. The study will also assess mitral regurgitation severity, symptoms, functional capacity, quality of life, heart failure events, and use of health care resources.
Source record: https://clinicaltrials.gov/study/NCT07741253
Facts
| registry id | NCT07741253 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | not reported |
| study type | INTERVENTIONAL |
| lead condition | Atrial Functional |
| sponsor | China National Center for Cardiovascular Diseases |
| sponsor class | OTHER_GOV |
| enrollment | 182 |
| start date | 2026-10-25 |
| primary completion | 2027-12 |
| completion | 2027-12 |
| results posted | not reported |
Conditions
- Atrial Functional
- Mitral Regurgitation (MR)
Interventions
- Transcatheter Edge-to-Edge Repair
Countries
- China
Intervention types: DEVICE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.